Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesOncosil Medical Ltd

Oncosil Medical Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.65 AUD -0.01 ( 2.26%)
Last update at 2026-11-12T03:23:00Z
VOLUME
23717
Market Cap
24.78M

Momentum Score

…

OncoSil Medical Limited, a medical device company, develops and commercializes localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company offers OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.65
Low
0.67
High
52 Week Price Range
0.37
Low
1.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Oncosil Medical develops an implantable targeted radiotherapy technology intended to treat solid tumours, with a primary clinical focus on locally advanced pancreatic cancer. Long-term growth may be driven by positive clinical trial outcomes, regulatory approvals, commercial rollout and partner or reimbursement agreements, and the company appears positioned to address an unmet need for more effective local therapies.

Key risks include clinical or regulatory failure, difficulty obtaining reimbursement or commercial traction, and funding risk given small-company development economics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.67
Dividend Yield
-
Revenue TTM
5.09M
Revenue Per Share
0.23
Gross Profit TTM
2.73M
Debt / Equity
0.00
ROE
-268.16%
Net Debt
-6.46M
ROCE
-288.11%
Diluted EPS TTM
-0.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -14.26M -15.10M -12.96M -11.34M -10.73M
Net income -10.86M -15.10M -11.91M -11.34M -10.73M
Selling general administrative - 7.54M 6.43M 6.56M 6.80M
Selling and marketing expenses - 0.29M 0.20M 0.13M 0.37M
Gross profit -6.20M -1.08M -0.99M -1.22M -0.74M
Reconciled depreciation - 0.04M 0.04M 0.18M 0.13M
Ebit -14.42M -15.10M -12.96M -11.34M -11.54M
Ebitda -14.36M -15.06M -12.91M -11.17M -11.41M
Depreciation and amortization 0.06M 0.04M 0.04M 0.18M 0.13M
Operating income -14.42M -15.49M -13.03M -11.34M -10.58M
Other operating expenses 16.10M 16.66M 13.55M 9.68M 9.84M
Interest expense 0.02M 0.00M 0.00M 0.00M 0.01M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.09M 0.07M 0.07M 0.01M
Net interest income - 0.09M 0.06M 0.05M -0.01M
Income tax expense -3.40M - -1.05M 1.16M -0.12M
Total revenue 1.68M 1.17M 0.52M 0.37M 0.23M
Total operating expenses 8.22M 14.41M 12.04M 11.51M 10.80M
Cost of revenue 7.88M 2.25M 1.51M 1.59M 0.97M
Total other income expense net 0.15M 0.39M 0.07M 1.16M 0.69M
Net income from continuing ops - -15.10M -11.91M -11.34M -10.73M
Net income applicable to common shares - -15.10M -11.91M -11.34M -10.73M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 10.31M 7.15M 6.36M 11.47M 13.07M
Other current assets 0.46M - 0.39M 0.12M 0.47M
Total liab 5.31M 4.04M 1.77M 1.59M 1.91M
Total stockholder equity 5.00M 3.10M 4.59M 9.88M 11.16M
Other current liab 2.08M - 0.79M 0.61M 0.84M
Common stock 105.46M - 90.09M 86.51M 79.91M
Capital stock - 96.43M - 86.51M 79.91M
Retained earnings -117.32M -107.46M -93.19M -84.37M -73.02M
Cash 6.48M 5.11M 4.50M 9.39M 11.28M
Total current liabilities 5.31M 4.03M 1.73M 1.57M 1.77M
Current deferred revenue - - 0.00M -0.15M -0.17M
Net debt -6.46M - -4.43M -9.22M -10.98M
Short term debt 0.01M - 0.03M 0.15M 0.17M
Short long term debt total 0.01M - 0.07M 0.17M 0.30M
Other stockholder equity - - - -2.14M -6.89M
Property plant equipment - - - 0.24M 0.32M
Total current assets 9.38M 6.72M 6.25M 11.23M 12.74M
Net tangible assets - - - 9.88M 11.16M
Short term investments - - - 0.12M 0.09M
Net receivables 2.44M 0.84M 1.35M 1.29M 0.91M
Inventory 0.01M - - - -
Accounts payable 3.21M 1.92M 0.91M 0.96M 0.93M
Accumulated other comprehensive income 16.86M - 7.69M 7.74M 4.28M
Non currrent assets other - - - -0.24M -0.32M
Non current assets total 0.93M 0.42M 0.11M 0.24M 0.32M
Capital lease obligations - 0.07M - 0.17M 0.30M
Long term debt total - - - 0.02M 0.14M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.01M -0.20M -0.06M -0.01M
Change to liabilities - - - -0.08M -0.07M
Total cashflows from investing activities -0.00M -0.01M -0.20M -0.06M -0.01M
Net borrowings - - - -0.19M -0.16M
Total cash from financing activities 11.86M 12.73M 6.13M 9.49M 9.16M
Change to operating activities - - - -0.08M -0.46M
Net income -10.86M -15.10M -11.91M -11.34M -10.73M
Change in cash 1.37M 0.61M -4.89M -1.89M -0.96M
Begin period cash flow 5.11M 4.50M 9.39M 11.28M 12.24M
End period cash flow 6.48M 5.11M 4.50M 9.39M 11.28M
Total cash from operating activities -10.47M -12.06M -10.82M -11.32M -10.11M
Issuance of capital stock - 12.78M 6.19M 9.67M 9.32M
Depreciation 0.06M - 0.04M 0.18M 0.19M
Change to inventory -0.01M - - - -
Change to account receivables -1.24M 0.23M 0.05M -0.38M 0.27M
Sale purchase of stock - 12.78M 6.19M 9.67M 9.32M
Other cashflows from financing activities -0.06M - -0.06M -0.19M -0.16M
Change to netincome - - - 0.38M 0.68M
Capital expenditures 0.00M 0.01M 0.20M 0.06M 0.01M
Change in working capital -0.25M 2.28M 0.50M -0.38M 0.27M
Stock based compensation - - 0.62M 0.39M 0.59M
Other non cash items 0.58M -14.34M -0.07M -0.15M 0.42M
Free cash flow -10.47M -12.08M -11.02M -11.37M -10.12M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
OSL
Oncosil Medical Ltd		 -0.01
2.26%		 0.65 - 4.51 4.87 4.81 10.43 -0.70
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Oncosil Medical Ltd

OncoSil Medical Limited, a medical device company, develops and commercializes localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company offers OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

7 Eden Park Drive, Macquarie Park, NSW, Australia, 2113

61 2 8935 9629

https://www.oncosil.com

Name Title Year Born
Mr. Nigel Lange CEO, MD & Director NA
Mr. Karl David Pechmann CFO & Company Sec. NA
Mr. Michael Warrener Global Sales & Marketing Director NA
Dr. David Charles James Global Head of Manufacturing Operations NA
Dr. Ralph Peters Chief Medical Officer NA
Mr. David Turner Head of Medical Affairs NA
Mr. Christian Dal Cin CFO & Company Secretary NA
Mr. Christian Dal Cin CFO & Company Secretary NA
Mr. Christian Dal Cin CFO & Company Secretary NA
Mr. Christian Dal Cin CFO & Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…